Literature DB >> 25224419

[Severe childhood atopic dermatitis].

Anis Mahfoudh, Inès Zaraa, Thouraya Amara, Hela Zribi, Dalenda El Euch, Mourad Mokni, Amel Ben Osman.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic relapsing eczematous skin disease. It represents one of the symptoms of atopic diathesis. DA affects usually infants and children. aim : The aim of our study is to draw up the epidemiological, clinical features, treatment and outcome of severe childhood AD through a hospital series. methods: A retrospective study of 24 cases of severe childhood AD hospitalized in the Dermatology Department of La Rabta hospital of Tunis was conducted during a 28 year-period (1981 - 2009). results: The hospital incidence of severe childhood AD was 0,085‰. Patient's mean age at the beginning was 14 months. The sex ratio H/F was 1.66. Cutaneous manifestations occurred preferentially in face (75%). Generalized eczema was observed in 37.5% of cases. Pruritus and xerosis were constant. The mean duration of hospitalization was 11 days. Topical corticosteroids was the most effective method of treating severe DA, associated with antiseptic solutions emollient and antihistaminic drugs. Infectious complications were noted in 50% of cases. Ocular complications were observed in 16.7% of cases. Recurrences were reported in 9 cases. Conclusion :AD is an inflammatory, chronically relapsing, and pruritic skin disorder developing in a xerotic skin. Severe AD in childhood is rare in Tunisia. It requires a good understanding of therapeutic modalities by the patient and his family. It is a cause of important morbidity and it may have a bad impact on quality of life.

Entities:  

Mesh:

Year:  2014        PMID: 25224419

Source DB:  PubMed          Journal:  Tunis Med        ISSN: 0041-4131


  1 in total

Review 1.  Ophthalmic manifestations of atopic dermatitis.

Authors:  Marta Pietruszyńska; Anna Zawadzka-Krajewska; Patrycja Duda; Monika Rogowska; Iwona Grabska-Liberek; Marek Kulus
Journal:  Postepy Dermatol Alergol       Date:  2018-11-06       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.